ADAR1 Capital Management’s Soleno Therapeutics SLNO Stock Holding History

ADAR1 Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-46,830	Closed	-$1.57M	–	335
2026 Q1	$1.57M	Buy	46,830 +5,000	+12%	+$196K	0.09%	128
2025 Q4	$1.94M	Buy	41,830 +16,600	+66%	+$910K	0.14%	102
2025 Q3	$1.71M	Buy	25,230 +7,900	+46%	+$586K	0.16%	84
2025 Q2	$1.45M	Sell	17,330 -1,500	-8%	-$112K	0.22%	68
2025 Q1	$1.35M	Sell	18,830 -18,000	-49%	-$876K	0.25%	71
2024 Q4	$1.66M	Buy	36,830 +26,830	+268%	+$1.39M	0.33%	58
2024 Q3	$505K	Sell	10,000 -29,929	-75%	-$1.43M	0.08%	114
2024 Q2	$1.63M	Buy	+39,929	New	+$1.69M	0.31%	49

ADAR1 Capital Management's SLNO Position: Q2 2026 in Review

ADAR1 Capital Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 46,830 shares — an estimated $1.57M sold.

ADAR1 Capital Management first reported a position in SLNO in Q2 2024 and held it in 8 quarters. The position peaked at $1.94M in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

ADAR1 Capital Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
ADAR1 Capital Management sold 46,830 Soleno Therapeutics shares in Q2 2026, an estimated $1.57M.
ADAR1 Capital Management first reported a position in Soleno Therapeutics in Q2 2024 and held it in 8 quarters.
ADAR1 Capital Management's Soleno Therapeutics position peaked at $1.94M in Q4 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.